Double-digit growth in the Europe region and in its biosimilars business helped to push up sales for Sandoz in the second quarter and first half of 2023.
Sandoz has delivered first-half results that reflect the strength of its business in Europe and the continuing expansion of its biosimilars segment, with double-digit growth for both aspects of the business helping to push up its sales in both the second quarter and first half of 2023.
Second-quarter sales came in at $2
Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.
Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.
One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.
